方法：将确诊的早期非缺血型CRVO患者116例116眼，按照完全随机数字法分成4组，每组各29眼，A组未给予治疗，B组给予复方樟柳碱注射液患侧眼的颞浅动脉旁皮下注射，C组给予曲安奈德注射液球周旁注射，D组给予曲安奈德与复方樟柳碱联合用药。在1、2、4、8、12wk观察记录每组的最佳矫正视力(best corrected visual acuity，BCVA)(EDTRS视力表)、出血情况、光学相干断层扫描(optical coherence tomography，OCT)检查黄斑中心厚度(central macular thickness，CMT)、眼底血管荧光造影(fundus fluoresecine angiography，FFA)检查有否转变成缺血型CRVO，累计各组3mo后的总疗效做组间比较。

结果：治疗后3mo与治疗前相比，A组BCVA平均值下降，CMT平均值升高； B、C、D三组BCVA平均值均升高，CMT平均值均下降； D组与A、B、C组间两两比较，BCVA、CMT变化差异具有统计学意义(P<0.05)； A、B、C组间两两比较，BCVA和CMT变化差异无统计学意义(P>0.05)。发生缺血型CRVO者，A组为8眼，B组6眼，C组5眼，D组2眼，差异无统计学意义(χ²=4.361，P=0.225)。火焰状出血A组为14眼，B组7例，C组9例，D组4例，差异有统计学意义(χ²=8.821，P=0.032)。

结论：曲安奈德联合复方樟柳碱在治疗早期非缺血型CRVO有重要的临床意义，使患者的视力得到更大程度的保护，减少缺血型CRVO的发生。

METHODS: One hundred and sixteen eyes in 116 patients with non ischemic CRVO in early stage were randomly divided into four groups, group A, group B, group C, and group D. Divided by the completely random data method, each group had 29 eyes. Group A received no treatment. Group B was given compound anisodine hydrobromide injection in subcutaneous injection besides superficial temporal artery of the eye. Group C was injected with triamcinolone acetonide beside eyeballs and Group D was given triamcinolone acetonide combined with compound anisodine hydrobromide injection. In each group, we observed and recorded the best corrected visual acuity(BCVA, using EDTRS chart), bleeding, optical coherence tomography(OCT)scanning for central macular thickness(CMT), fundus fluorescence angiography(FFA)imaging check for the possibility of ischemic CRVO at 1, 2, 4, 8 and 12wk respectively. The total curative effect after 3mo was being compared among the three groups.

RESULTS: After 12 weeks' treatment, the mean BCVA was lower and the mean CMT was higher in group A than those before the treatment. The mean BCVA was increased and the mean CMT decreased in group B, C and D after treated for 3mo. Comparing Group D with the rest groups, the variation of BCVA and CMT had statistical significance(P<0.05).The variation of BCVA and CMT had no statistical significance in the multiple comparison among group A, group B and group C(P>0.05). Ischemic CRVO was found in 8 cases of group A, 6 cases of group B, 5 cases of group C, and 2 cases of group D,and the difference was not statistically significant(χ²=4.361; P=0.225). Flame-shaped bleeding was found in 14 cases of group A, 7 cases of group B, 9 cases of group C and 4 cases of group D and the difference was statistically significant(χ²=8.821; P=0.032).

CONCLUSION: The combination of triamcinolone acetonide and compound anisodine hydrobromide injection has important clinical significance on protecting eyesight of patients to a greater degree and reducing ischemic CRVO in the early non ischemic stage.